The Radiation Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Radiation Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Radiation Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Radiation Injury and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Radiation Injury by ten companies/universities/institutes. The top development phase for Radiation Injury is preclinical with eight drugs in that stage. The Radiation Injury pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Radiation Injury pipeline products market are: PharmaIN, Xequel Bio and Jiangsu Hengrui Medicine.
The key targets in the Radiation Injury pipeline products market include Histone Acetyltransferase p300 (E1A Associated Protein p300 or EP300 or EC 2.3.1.48), Gap Junction Alpha 1 Protein (Connexin 43 or Gap Junction 43 Kda Heart Protein or GJA1), and Free Radical.
The key mechanisms of action in the Radiation Injury pipeline product include Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC 1.14.13.39) Inhibitor with one drug in Preclinical. The Radiation Injury pipeline products include five routes of administration with the top ROA being Parenteral and five key molecule types in the Radiation Injury pipeline products market including Small Molecule, and Synthetic Peptide.
Radiation Injury overview
Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.
For a complete picture of Radiation Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
